# Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

> **NCT04707391** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1250 (actual)

## Conditions studied

- Meningitis, Meningococcal

## Interventions

- **COMBINATION_PRODUCT:** MenABCWY vaccine
- **COMBINATION_PRODUCT:** Placebo
- **BIOLOGICAL:** MenACWY vaccine
- **COMBINATION_PRODUCT:** MenB vaccine

## Key facts

- **NCT ID:** NCT04707391
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-25
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-09-29
- **Target enrollment:** 1250 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707391, "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04707391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*